Biospecimen Collection (NCT06577441)

Name: Biospecimen Collection trial for Myelodysplastic Syndrome (NCT06577441)
Uploaded: 2026-10-31T06:17:18.597Z
Duration: 1 min 17 s
Description: Biospecimen Collection trial for Myelodysplastic Syndrome (NCT06577441). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06577441.

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial): a one-minute explainerNCT065774411 min

Biospecimen Collection trial for Myelodysplastic Syndrome (NCT06577441). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with higher-risk, IDH2-mutated myelodysplastic syndrome, an IPSS-R score of at least 4, and no prior hypomethylating treatment. MyeloMATCH assignment is required.

The idea: compare oral decitabine/cedazuridine alone with added enasidenib. Decitabine targets abnormal marrow cells; cedazuridine slows its breakdown, while enasidenib targets mutant IDH2. Treatment uses 28-day cycles. Some patients can switch to combination treatment after six cycles.

This phase 2 study plans 54 patients. Anand Patel leads the NCI-sponsored study, with 143 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.